A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Hypertension

Interventions

DRUG

Aliskiren 3.125 mini-tablets

Oral mini-tablets (3.125 mg) of aliskiren once each morning

Trial Locations (5)

Investigative Site, Louisville

Investigative Site, Brussels

Investigative Site, Brasília

Investigative Site, Budapest

Investigative Site, Warsaw